Abstracts tagged "Cardiovascular disease"

Abstract Number: 1477 • 2016 ACR/ARHP Annual Meeting
Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Eirik Ikdahl¹, Silvia Rollefstad², Grunde Wibetoe³, Anne Salberg⁴, Dag Magnar Soldal⁵, Inge C Olsen⁶, Tore K Kvien⁷, Anne Grete Semb¹ and Glenn Haugeberg⁸, ¹Preventive Cardio-Rheuma clinic, Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁵Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁸Martina Hansens Hospital, Bærum, Norway
Background/Purpose: Antihypertensives (antiHT) and lipid lowering therapies (LLT) prevent cardiovascular disease (CVD) effectively. It has been reported that patients with rheumatoid arthritis (RA) receive suboptimal…
Abstract Number: 1727 • 2016 ACR/ARHP Annual Meeting
Association Between Biologic Therapies and Major Adverse Cardiac Events or Cardiac Heart Failure in Psoriatic Arthritis or Psoriasis: A Meta-Analysis
Benedicte Champs, Rheumatology, Medecine Toulouse Purpan Hospital, Lescure d'albigeois, France
Association between biologic therapies and major adverse cardiac events or cardiac heart failure in psoriatic arthritis or psoriasis: a meta-analysis. 1Champs B, 1Degboe Y, 1Ruyssen-Witrand…
Abstract Number: 2359 • 2016 ACR/ARHP Annual Meeting
Dose-Related Risks of Cardiovascular, Gastrointestinal, and Renal Adverse Events Associated with Meloxicam Among Patients with Osteoarthritis: An Observational Study Using US Claims Data
Elaine Hoffman¹, Deirdre M. Mladsi¹, Byron Cryer², William Hopkins³, D. Craig Brater⁴, Rohan Parikh¹, Ravi Goyal¹, Jordi Castellsague⁵, Dana Stafkey-Mailey⁶ and Clarence Young⁷, ¹Health Economics, RTI Health Solutions, Research Triangle Park, NC, ²University of Texas Southwestern Medical School, Dallas, TX, ³Fletcher Allen Health Care, University of Vermont College of Medicine, Burlington, VT, ⁴Indiana University School of Medicine, Bloomington, IN, ⁵Epidemiology, RTI Health Solutions, Barcelona, Spain, ⁶Xcenda, AmerisourceBergen, Palm Harbor, FL, ⁷Iroko Pharmaceuticals, LLC, Philadelphia, PA
Background/Purpose: Safety studies have shown that risks associated with non-steroidal anti-inflammatory drugs (NSAIDs) are related to dose; however, there is little evidence regarding this dose-toxicity…
Abstract Number: 232 • 2016 ACR/ARHP Annual Meeting
Impact of Gout Flare Prophylaxis and Urate-Lowering Therapy on Endothelial Function, Smooth Muscle Responsiveness and Markers of Inflammation: Results of a Prospective Observational Pilot Study
Talia Igel^1,2, Aaron Garza Romero², Virginia Pike³, Stuart Katz⁴, Binita Shah⁵, Irina Dektiarev⁴, Svetlana Krasnokutsky Samuels⁶ and Michael H. Pillinger⁷, ¹Monash University School of Medicine, Melbourne, Australia, ²Medicine/Rheumatology, NYU School of Medicine, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ⁴Medicine/Cardiology, NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, Division of Cardiology, New York, NY, ⁶Svetlana Krasnokutsky, NYU Hospital for Joint Diseases, New York, NY, ⁷NYU School of Medicine, New York, NY
Background/Purpose: To date, most studies of gout and cardiovascular disease have been cross-sectional or retrospective, and have addressed the outcome of acute coronary syndromes. Less…
Abstract Number: 896 • 2016 ACR/ARHP Annual Meeting
Risk for Cardiovascular Disease in Giant Cell Arteritis and Polymyalgia Rheumatica
Florencia Beatriz Mollerach¹, Emmanuel Bertiller¹, Maria de los Angeles Gallardo², Maximiliano José Martinez¹, Marina Scolnik³, Javier Rosa¹, Luis J. Catoggio⁴ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, CABA, Argentina, ³Rheumatology Section, Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: chronic inflammatory diseases are at a substantially increased risk of cardiovascular events (CVE). Scarce data is available in patients with Giant cell arteritis (GCA)…
Abstract Number: 1479 • 2016 ACR/ARHP Annual Meeting
Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study
Jung Su Eun¹, Eun Song Lee², Jong Wan Kang¹, Na Ri Kim¹, Ji Hun Kim¹, Jin Young Kang¹, Eon Jeong Nam³ and Young Mo Kang¹, ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ²Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher risk of cardiovascular disease (CVD) and premature mortality, compared to the general population. Inflammatory burden and conventional…
Abstract Number: 1782 • 2016 ACR/ARHP Annual Meeting
Subclinical Myocarditis in Systemic Lupus Erythematosus Patients without Cardiovascular Disease
Laura Geraldino-Pardilla¹, Thania Perez², Sabahat Bokhari³, Joan Bathon⁴ and Anca D. Askanase⁵, ¹Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Columbia University College of Physicians & Surgeons, New York, NY, ³Cardiology, Columbia University College of Physicians & Surgeons, NY, NY, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose : Cardiovascular disease (CVD) remains a leading cause of death in SLE. Lupus patients have a 2-3 fold increased risk to develop heart failure…
Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Daisy Bang¹, Jinfeng Xu², Robert T. Keenan³, Virginia Pike¹, Aaron Lehmann¹, Craig T. Tenner⁴, Daria Crittenden¹, Michael H. Pillinger¹ and Svetlana Krasnokutsky¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Biostatistics, New York University School of Medicine, New York, NY, ³Rheumatology, Duke University, Durham, NC, ⁴Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
Abstract Number: 1498 • 2015 ACR/ARHP Annual Meeting
Engaging Clinic Staff in Work System Redesign to Adapt a Hypertension Protocol for Rheumatology
Edmond Ramly¹, Diane Lauver² and Christie M. Bartels³, ¹Industrial and Systems Engineering, University of Wisconsin-Madison College of Engineering, Madison, WI, ²University of Wisconsin-Madison School of Nursing, Madison, WI, ³Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health (SMPH), Madison, WI
Background/Purpose: Despite routine blood pressure (BP) measurement by clinic staff, we reported that rheumatologists discussed elevated BPs in <1/3 of visits leading to missed opportunities…
Abstract Number: 1563 • 2015 ACR/ARHP Annual Meeting
Dyslipidemia and Hyperglycemia, Two Cardiometabolic Parameters, Independently Predict Poor Outcome in Early Rheumatoid Arthritis: Results from Espoir Cohort
Claire I. Daien¹, Jeremie Sellam², Nathalie Rincheval³, Bruno Fautrel⁴, Alain Saraux⁵, Francis Berenbaum⁶, Jacques Morel¹, Jean-Pierre Daures⁷ and Bernard Combe⁸, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Department of Rheumatology, Assistance Publique – Hôpitaux de Paris, Saint-Antoine Hospital, Paris, France, ³Biostatistic, EA 2415, Epidemiology unit, Montpellier, France, ⁴Rheumatology, AP-HP Pitié-Salpêtrière Hospital / Pierre and Marie Curie University Paris 6 GRC-08 (EEMOIS), Paris, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶Rheumatology and Paris VI University, Saint-Antoine Hospital, Paris, France, ⁷Biostatistic, EA 2415 Epidemiology unit, Montpellier, France, ⁸Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Previous studies showed that obesity in patients with rheumatoid arthritis (RA) is associated with higher disease activity. Beyond obesity, cardiometabolic disturbances may impact the…
Abstract Number: 1972 • 2015 ACR/ARHP Annual Meeting
Cardiovascular and Cerebrovascular Disease and Social Deprivation in Patients with Giant Cell Arteritis
Joanna Robson¹, Amit Kiran², Andrew Hutchings³, Joseph Maskell⁴, Nigel K Arden⁵, Willie Hamilton⁶, Bhaskar Dasgupta^7,8 and Raashid Luqmani⁹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ³Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom, ⁴Faculty of Medicine, University of Southampton, Southampton, United Kingdom, ⁵Oxford NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom, ⁶Primary Care, University of Exeter, Exeter, United Kingdom, ⁷Southend University Hospital, Southend, United Kingdom, ⁸Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA) is the most common form of vasculitis in the UK, with an incidence of 2.2 cases per 10,000 person-years. Cerebrovascular…
Abstract Number: 2892 • 2015 ACR/ARHP Annual Meeting
Statin Treatment in Patients with Ankylosing Spondylitis
Grunde Wibetoe¹, Eirik Ikdahl¹, Tore K. Kvien², Silvia Rollefstad¹ and Anne Grete Semb³, ¹Preventive Cardio-Rheuma Clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Patients with ankylosing spondylitis (AS) have increased risk of cardiovascular disease (CVD). In the general population, CVD risk reduction can be achieved by lipid…
Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Jenni E Kauppi¹, Tuomo Nieminen^2,3, Mika Kähönen^4,5, Anne Kerola⁶, Antti Jula⁷, Jaana Leiviskä⁸ and Markku J. Kauppi^9,10, ¹School of medicine, University of Tampere, Tampere, Finland, ²Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, ⁶Faculty of Medicine, University of Helsinki, Helsinki, Finland, ⁷Department of Health, National Institute for Health and Welfare, Turku, Finland, ⁸Department of Health, National Institute for Health and Welfare, Helsinki, Finland, ⁹School of Medicine, University of Tampere, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
Abstract Number: 1503 • 2015 ACR/ARHP Annual Meeting
A Systematic Screening of Comorbidities By the Rheumatologist in Inflammatory Rheumatisms Impacts Chronic Disease Care
Claire I. Daien¹, Amandine Tubery², Guilhem du Cailar³, Aurore Royanez⁴, Thibault Mura⁵, Marie-Christine Picot⁶, Rodolphe Bourret⁷, François Roubille⁸, Jean Bousquet⁹, Jacques Morel¹, Pierre Fesler³ and Bernard Combe¹⁰, ¹Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France, ²Nîmes University Hospital, Rheumatology Department, Nimes, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology and Pharmacology, Montpellier, France, ⁵CIC, Hopital Gui De Chauliac, Montpellier, France, ⁶DIM, Montpellier, France, ⁷Direction Teaching hospital, Montpellier, France, ⁸Cardiology, Montpellier, France, ⁹Pneumology, Montpellier, France, ¹⁰Rheumatology, Hopital Lapeyronie, Montpellier, France
Background/Purpose: Patients with inflammatory rheumatisms especially rheumatoid arthritis (RA) have a greater risk of cardiovascular diseases (CVD), infections, chronic respiratory diseases (CRD) and osteoporosis. As…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].